T1	Participants 378 545	85 HCC patients after transcatheter arterial chemoembolization and radiofrequency ablation therapy were randomized to immunotherapy group and no adjuvant therapy group
T2	Participants 757 863	All patients were screened by computed tomography every 2 months to observe the tumor recurrent conditions
